
ANL Stock Forecast & Price Target
ANL Analyst Ratings
Bulls say
Adlai Nortye is a clinical-stage company developing promising cancer therapies, including the RAS-targeting drug AN9025, with potential for 180% growth according to analysts. Despite potential competition and concerns over toxicities, AN9025 has shown strong preclinical data and has a strategic partnership for development in China. Adlai's second drug, AN4035, has shown potential as a targeted antibody drug conjugate, and the company has a promising valuation and potential for growth in the near future.
Bears say
Adlai Nortye is a clinical-stage company developing cancer therapies that may face challenges in generating significant revenue from commercializing its product candidates. With a limited competitive landscape in the 1L mPDAC market, and challenges with response rates and resistances seen in similar RAS-targeting therapies, Adlai's pan-RAS and immunotherapy candidates may have a less compelling profile than its competitors. Additionally, while Adlai's financial position may support clinical development for its pipeline, its late entry into the market and potential safety concerns may limit its success in the future.
This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.
ANL Analyst Forecast & Price Prediction
Start investing in ANL
Order type
Buy in
Order amount
Est. shares
0 shares